HPAPIs and Cytotoxic Drugs Manufacturing Market to Evolve Rapidly
Roots Analysis has announced the addition of “HPAPIs and Cytotoxic Drugs Manufacturing Market” report to their portfolio. The report provides an extensive study of the contract manufacturing opportunity for this rapidly expanding market. It identifies various CMOs active in this space, their capabilities with respect to manufacturing of HPAPIs and cytotoxic drugs, scale of operation (laboratory/development/commercial), occupational exposure limits (OELs) and geographic location/spread of the facilities. The focus of this report is primarily to understand the likely future evolution of HPAPIs and cytotoxics over the next decade.
Shefali Asija, the principal analyst, said: “Due to their numerous advantages and increased applications in treatment of cancer and other disorders, HPAPIs and cytotoxics have emerged as one of the key focus areas of researchers and manufacturers across the globe. Despite the fact that production of HPAPIs and cytotoxic drugs require specialised containment requirements making it a capital extensive business, a lot of CMOs are involved actively in the market.”
The report examines insights gathered from interviews of important stakeholders such as Corden Pharma, Helsinn, Catalent Pharma Solutions and Piramal Healthcare. Asija further stated: “Majority of our work is supported by detailed research. For the purposes of this report, we studied close to 60 investment programmes which have taken place since 2004. The success of the market lies in the increasing number of collaborations between contract manufacturers and pharmaceutical companies.” The firm had previously done a focused study on ADC contract manufacturing market.
Key topics covered in the latest report are
• Analysis of contract manufacturers involved in HPAPIs and cytotoxics manufacturing
• Pharmaceutical companies with in-house manufacturing
• Future market evolution
• Recent deals and partnerships
• Investment programs
• Regulatory landscape
• Special focus on ADC contract manufacturing
• Profiles of leading companies
• Case studies on companies providing ‘one stop shop’ service.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance